HO-3867

HO-3867 is a synthetic diarylidenylpiperidone analog of curcumin designed as a **selective inhibitor of signal transducer and activator of transcription 3 (STAT3)**, showing promising preclinical anticancer activity and low toxicity. It exhibits selective cytotoxicity toward cancer cells, particularly those with mutant p53, while sparing healthy cells. HO-3867 induces apoptosis via two main mechanisms: **direct STAT3 inhibition** and **generation of reactive oxygen species (ROS)** leading to ER stress and downstream pro-apoptotic signaling. Additional targets include inhibition of fatty acid synthase (FAS) and focal adhesion kinase (FAK), both of which are relevant to cancer cell migration and proliferation. Its anticancer potential has been demonstrated in multiple tumor models, including ovarian, pancreatic, breast, colon, and liver cancers, as well as chemotherapy-resistant cancer cell populations. Notably, it has shown strong efficacy in ovarian cancer cell lines and xenograft models, with oral bioavailability and minimal toxicity to normal tissues. HO-3867 also demonstrates the ability to reactivate mutant p53, contributing to its selective pro-apoptotic effects in cancer cells[1][2][3][4][5][6].